Company Analysis

Aldeyra Therapeutics, Inc. (ALDX)

Nasdaq: ALDX · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2005
Grade6.5
◀ Past 6.9● Present 6.1▶ Future 6.6
6 est.

Who runs Aldeyra Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Brady Todd C
President and CEO. First filing May 2014, latest Jun 5, 2026, 11 filings in all.
Officers reporting now
3
of 10 people with a filing in the last fifteen months
Directors reporting now
7
19 people on the record since 2014
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Brady Todd CPresident and CEOMay 2014Jun 5, 2026none
Alfieri MichaelPrincipal Financial OfficerSep 2024Mar 19, 2026none
Machatha StephenChief Development OfficerDec 2020Aug 13, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bronstein BendirectorMay 2014Jun 11, 2026none
Clark William DdirectorApr 2025Jun 11, 2026none
Deptula-Hicks Darlene MdirectorJun 2026Jun 11, 2026none
Douglas RicharddirectorSep 2016Jun 11, 2026none
Miller-Rich NancydirectorJan 2020Jun 11, 2026none
Phillips Gary M.directorMay 2014Jun 11, 2026none
Walker NealdirectorMay 2014Jun 11, 2026none
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ALDX · research, not advice